Stock BIO BIOTON S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BIOTON S.A.

Equities

BIO

PLBIOTN00029

Biotechnology & Medical Research

Market Closed - Warsaw S.E.
Other stock markets
 11:55:40 2024-04-29 am EDT 		5-day change 1st Jan Change
3.505 PLN 0.00% Intraday chart for BIOTON S.A. -0.43% -1.82%
Mar. 28 BIOTON S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 BIOTON S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 434.5 326.3 367.5 359.3 289.4 306.5
Enterprise Value (EV) 1 538.4 446.5 455.3 460.6 356.4 371.3
P/E ratio 16.5 x -2.57 x 11 x 140 x 204 x 135 x
Yield - - - - - -
Capitalization / Revenue 1.8 x 1.62 x 1.66 x 2.2 x 1.24 x 1.69 x
EV / Revenue 2.23 x 2.21 x 2.05 x 2.82 x 1.53 x 2.04 x
EV / EBITDA -19.8 x 30.2 x 5.39 x 11.2 x 7.15 x 17.8 x
EV / FCF 37.3 x 28.1 x 16.1 x -32.3 x 10.2 x -38.9 x
FCF Yield 2.68% 3.56% 6.22% -3.1% 9.82% -2.57%
Price to Book 0.61 x 0.56 x 0.6 x 0.58 x 0.48 x 0.51 x
Nbr of stocks (in thousands) 85,864 85,864 84,864 85,864 85,864 85,864
Reference price 2 5.060 3.800 4.330 4.185 3.370 3.570
Announcement Date 4/30/19 4/14/20 4/15/21 3/31/22 3/31/23 3/28/24
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 241.2 202 221.8 163 233.2 181.6
EBITDA 1 -27.22 14.78 84.46 41.08 49.87 20.88
EBIT 1 -54 -13.67 55.31 13.45 24.15 -3.723
Operating Margin -22.39% -6.77% 24.94% 8.25% 10.36% -2.05%
Earnings before Tax (EBT) 1 15.17 -162.1 41.61 8.331 4.952 7.234
Net income 1 26.27 -126.7 33.92 2.882 1.421 2.275
Net margin 10.89% -62.71% 15.29% 1.77% 0.61% 1.25%
EPS 2 0.3059 -1.480 0.3950 0.0300 0.0165 0.0265
Free Cash Flow 1 14.42 15.91 28.32 -14.28 35.01 -9.546
FCF margin 5.98% 7.87% 12.77% -8.76% 15.02% -5.26%
FCF Conversion (EBITDA) - 107.6% 33.53% - 70.21% -
FCF Conversion (Net income) 54.89% - 83.49% - 2,463.97% -
Dividend per Share - - - - - -
Announcement Date 4/30/19 4/14/20 4/15/21 3/31/22 3/31/23 3/28/24
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 104 120 87.9 101 67.1 64.8
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -3.816 x 8.134 x 1.04 x 2.464 x 1.345 x 3.104 x
Free Cash Flow 1 14.4 15.9 28.3 -14.3 35 -9.55
ROE (net income / shareholders' equity) 3.61% -19.6% 5.63% 0.46% 0.23% 0.38%
ROA (Net income/ Total Assets) -3.2% -0.9% 3.95% 0.97% 1.82% -0.29%
Assets 1 -820.2 14,024 859.6 296.9 78.06 -797.4
Book Value Per Share 2 8.300 6.780 7.220 7.250 7.060 7.060
Cash Flow per Share 2 0.0900 0.0800 0.2600 0.1000 0.1100 0.0500
Capex 1 43.4 53.5 4.68 12.9 29.6 44.2
Capex / Sales 18.02% 26.46% 2.11% 7.91% 12.69% 24.32%
Announcement Date 4/30/19 4/14/20 4/15/21 3/31/22 3/31/23 3/28/24
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOTON S.A. Stock BIOTON S.A.
-1.82% 74.34M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-16.67% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIO Stock
  4. Financials BIOTON S.A.